BOULS Stock Overview

Develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. More details

BOULS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	1/6
Financial Health	2/6
Dividends	3/6

Rewards

Trading at 73.3% below our estimate of its fair value

Earnings are forecast to grow 33% per year

Became profitable this year

Risk Analysis

High level of non-cash earnings

Shares are highly illiquid

Debt is not well covered by operating cash flow

Does not have a meaningful market cap (SEK311M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Boule Diagnostics AB (publ) Competitors

EKF Diagnostics Holdings

AIM:EKF

UK£122.7m

NIOX Group

AIM:NIOX

UK£250.7m

Cambridge Nutritional Sciences

AIM:CNSL

UK£6.8m

RUA Life Sciences

AIM:RUA

UK£6.7m

Price History & Performance

Summary of share price highs, lows and changes for Boule Diagnostics
Historical stock prices
Current Share Price	SEK 26.30
52 Week High	SEK 37.80
52 Week Low	SEK 26.30
Beta	0.82
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-56.39%
5 Year Change	-59.92%
Change since IPO	33.17%

Recent updates

Shareholder Returns

	BOULS	GB Medical Equipment	GB Market
7D	0%	-0.4%	0.8%
1Y	n/a	-9.1%	4.4%

Return vs Industry: Insufficient data to determine how BOULS performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how BOULS performed against the UK Market.

Price Volatility

Is BOULS's price volatile compared to industry and market?
BOULS volatility
BOULS Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: BOULS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BOULS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1956	200	Jesper Soderqvist	www.boule.com

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally.

Boule Diagnostics AB (publ) Fundamentals Summary

How do Boule Diagnostics's earnings and revenue compare to its market cap?
BOULS fundamental statistics
Market cap	SEK 310.66m
Earnings (TTM)	SEK 31.87m
Revenue (TTM)	SEK 525.34m

9.7x

P/E Ratio

0.6x

P/S Ratio

Is BOULS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOULS income statement (TTM)
Revenue	SEK 525.34m
Cost of Revenue	SEK 307.51m
Gross Profit	SEK 217.84m
Other Expenses	SEK 185.96m
Earnings	SEK 31.87m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)	1.64
Gross Margin	41.47%
Net Profit Margin	6.07%
Debt/Equity Ratio	62.6%

How did BOULS perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

35%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/10/29 15:36
End of Day Share Price	2022/08/01 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Boule Diagnostics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jakob Lembke	ABG Sundal Collier Sponsored
null null	ABG Sundal Collier Sponsored
Christian Lee	Pareto Securities